StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Provectus Biopharmaceuticals's total debt was $23.62K at Dec 31, 2025. For fiscal 2025 it was $23.62K.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$23.62K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$23.62K–
Q3 FY2025Sep 30, 2025$23.62K–
Q3 FY2020Sep 30, 2020$39.06K–
Q2 FY2020Jun 30, 2020$39.06K–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?